Fluoroquinolones - Open Access .click

Results 1 to 10 of about 50,121 (149)

Fluoroquinolone Antimicrobial Agents [PDF]

New England Journal of Medicine, 1989
The fluoroquinolones, a new class of potent orally absorbed antimicrobial agents, are reviewed, considering structure, mechanisms of action and resistance, spectrum, variables affecting activity in vitro, pharmacokinetic properties, clinical efficacy, emergence of resistance, and tolerability. The primary bacterial target is the enzyme deoxyribonucleic
D C, Hooper, J S, Wolfson
openaire +3 more sources

Safety of Short-Term Trimethoprim-Sulfamethoxazole Use for Uncomplicated Cystitis: A Nationwide Retrospective Cohort Study. [PDF]

Pharmacoepidemiol Drug Saf
ABSTRACT Background Trimethoprim–sulfamethoxazole (TMP–SMX) is associated with hypersensitivity and other adverse reactions. East Asian–specific genetic susceptibility may increase severe adverse events, limiting the therapeutic use of TMP–SMX for uncomplicated cystitis in Japan.
Taniguchi J, Aso S, Yasunaga H.
europepmc +2 more sources

Cardiotoxicity of fluoroquinolones [PDF]

Journal of Antimicrobial Chemotherapy, 2002
Currently marketed fluoroquinolones enjoy an admirable safety profile that is not matched by any other antibiotic group. The widespread use of fluoroquinolones in the elderly, who are susceptible to cardiac arrhythmias because of underlying heart diseases, metabolic derangement and use of anti-arrhythmic agents and other medications that prolong the QT
Ethan, Rubinstein, John, Camm
openaire +2 more sources

[Fluoroquinolones].

Duodecim; laaketieteellinen aikakauskirja, 1988
We reviewed, the structure, pharmacokinetic properties, mode of actions, antibacterial spectrum, therapeutic dosage and side effects of fluoroquinolones in this article.
P, Huovinen, V, Valtonen
+6 more sources

Oral fluoroquinolone use and the risk of aortic and mitral valve regurgitation: a nationwide cohort study. [PDF]

BMJ Open
Nibell O, Björk J, Inghammar M.
europepmc +1 more source

Gyrase and Topoisomerase IV as Antibacterial Targets for Gepotidacin and Zoliflodacin: Teaching Old Enzymes New Tricks. [PDF]

Int J Mol Sci
Osheroff N.
europepmc +1 more source

Risk of drug eruption associated with the use of tetracyclines, macrolides, and fluoroquinolones: real-world evidence from a pharmacovigilance study utilizing the FDA adverse event reporting system. [PDF]

Saudi Pharm J
Alshammari TM.
europepmc +1 more source

Clinical experience with fluoroquinolones for treatment of severe Chlamydia psittaci pneumonia with invasive mechanical ventilation in ICU: a retrospective study. [PDF]